In-vitro Chemosensitivity Test for Colorectal Cancer using an Adenosine-triphosphate-based Chemotherapy Response Assay (ATP-CRA).

Huh, Jung Wook; Park, Yoon Ah; Sohn, Seung Kook; Choi, Sung Ho

doi:10.3393/jksc.2007.23.3.172

Articles

Page Path: HOME > J Korean Soc Coloproctol > Volume 23(3); 2007 > Article

Original Article
In-vitro Chemosensitivity Test for Colorectal Cancer using an Adenosine-triphosphate-based Chemotherapy Response Assay (ATP-CRA).: Huh, Jung Wook , Park, Yoon Ah , Sohn, Seung Kook , Choi, Sung Ho; Journal of the Korean Society of Coloproctology 2007;23(3):172-179
DOI: https://doi.org/10.3393/jksc.2007.23.3.172

¹Department of Surgery, Yongdong Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. sksohn@yumc.yonsei.ac.kr
²ISU ABXIS CO., LTD, Seoul, Korea.

prev next

2,631 Views
16 Download
3 Crossref
0 Scopus

Full Article

Download PDF

Abstract

Purpose
The adenosine-triphosphate-based chemotherapy response assay (ATP-CRA) is a well-documented and validated technology for individualizing chemotherapy in cancer patients. We evaluate the feasibility of ATP-CRA in colorectal cancer patients. This study will illustrate the assay's success rate, the mean coefficient of variation, and the turnaround time as a validation tool for a chemosensitivity test. Methods: A total of 118 patients, treated by surgery between June 2004 and September 2005 were evaluated for chemosensitivity to seven anticancer agents (5-fluorouracil (5-FU), oxaliplatin, irinotecan, epirubicin, etoposide, gemcitabine, and paclitaxel) by using an ATP-CRA. To allow a comparison between samples, we calculated the chemosensitivity index (CI) based on the percentage cell death rate (CDR, %) at each test drug concentration.
Results
The assay success rate was 85.5% (118/138), and the mean coefficient of variation, indicating intra-assay error level, was 9.2%. CDR measured at a therapeutic peak plasma concentration ranged from 0% to 93.6% with a median of 31.0% for 5-FU, 28.5% for oxaliplatin, 34.0% for irinotecan, 25.0% for epirubicin, 21.0% for etoposide, 22.0% for gemcitabine, and 25.2% for paclitaxel. According to the CI, the most sensitive drug varied from patient to patients 10.9% for 5-FU, 10.9% for oxaliplatin, 24.7% for irinotecan, 11.8% for epirubicin, 22.4% for etoposide, 1.1% for gemcitabine, and 23.3% for paclitaxel. Conclusions: Our data suggest that the ATP- CRA is a feasible in-vitro chemosensitivity test in colorectal cancer and that patients show heterogeneous chemosensitivity. A study evaluating the predictive value of ATP-CRA directed therapy is needed to determine the clinical usefulness of the test.

Keywords: Chemosensitivity test;ATP-CRA;Colorectal cancer

Figure & Data

References

Citations

Citations to this article as recorded by

Correlation between the molecular subtype of breast cancer and thein vitroadenosine triphosphate-based chemosensitivity assay
Jina Chang, Anbok Lee, Jihyun Lee, Woosung Lim, Sun Hee Sung, Byung-In Moon
Journal of the Korean Surgical Society.2013; 84(6): 313. CrossRef
Heterogeneity of Adenosine Triphosphate-Based Chemotherapy Response Assay in Colorectal Cancer - Secondary Publication
Jung Wook Huh, Yoon Ah Park, Kang Young Lee, Seung-Kook Sohn
Yonsei Medical Journal.2009; 50(5): 697. CrossRef
Complete Remission of Unresectable Colon Cancer after Preoperative Chemotherapy Selected by Adenosine Triphosphate-Based Chemotherapy Response Assay
Jung Wook Huh, Yoon Ah Park, Eun Joo Jung, Kang Young Lee, Ji Eun Kwon, Seung-Kook Sohn
Journal of Korean Medical Science.2008; 23(5): 916. CrossRef

Cited

Related articles